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The human carboxylesterase 1 (CES1) gene encodes for the enzyme carboxylesterase 1, a serine esterase governing both metabolic
deactivation and activation of numerous therapeutic agents. During the course of a study of the pharmacokinetics of the methyl ester
racemic psychostimulantmethylphenidate, profoundly elevatedmethylphenidate plasma concentrations, unprecedented distortions in
isomer disposition, and increases in hemodynamic measures were observed in a subject of European descent. These observations led to
a focused study of the subject’s CES1 gene. DNA sequencing detected two coding region single-nucleotide mutations located in exons 4
and 6. Themutation in exon 4 is located in codon 143 and leads to a nonconservative substitution, p.Gly143Glu. A deletion in exon 6 at
codon 260 results in a frameshift mutation, p.Asp260fs, altering residues 260–299 before truncating at a premature stop codon. The mi-
nor allele frequency of p.Gly143Glu was determined to be 3.7%, 4.3%, 2.0%, and 0% in white, black, Hispanic, and Asian populations,
respectively. Of 925 individual DNA samples examined, none carried the p.Asp260fs, indicating it is an extremely rare mutation. In vitro
functional studies demonstrated the catalytic functions of both p.Gly143Glu and p.Asp260fs are substantially impaired, resulting
in a complete loss of hydrolytic activity toward methylphenidate. When a more sensitive esterase substrate, p-nitrophenyl acetate
was utilized, only 21.4% and 0.6% catalytic efﬁciency (Vmax/Km) were determined in p.Gly143Glu and p.Asp260fs, respectively,
compared to the wild-type enzyme. These ﬁndings indicate that speciﬁc CES1 gene variants can lead to clinically signiﬁcant alterations
in pharmacokinetics and drug response of carboxylesterase 1 substrates.Introduction
The carboxylesterase 1 (CES1) gene (MIM 114835) encodes
for human carboxylesterase 1 (CES1), the principal enzyme
governing the metabolism of the most widely prescribed
psychostimulant methylphenidate (MPH), and is involved
in the metabolism of numerous other therapeutic medica-
tions as well as some illicit drugs such as heroin and
cocaine.1,2 Further, it is responsible for themetabolic activa-
tion of a number of ester prodrugs.3 Single-nucleotide
polymorphisms (SNPs) can signiﬁcantly inﬂuence the me-
tabolism and disposition of many therapeutic agents.
MPH is widely considered the ‘‘gold standard’’ in treating
attention-deﬁcit/hyperactivity disorder (ADHD [MIM
143465]), which has an estimated worldwide prevalence
of 8%–12%.4,5 Up to 30% of patients receiving psychosti-
mulants such as MPH are either nonresponders or are in-
tolerant to treatment. Additionally, available long-term
studies (i.e., >1 year) suggest only 50% of children con-
tinue MPH treatment after initiation of therapy.6 Predict-
ing a therapeutic drug response in individual patients is
not presently possible with most research ﬁnding no neu-
rological, psychological, or physical characteristics that
can serve as reliable predictors of response, and dosing
these agents remains largely an empiric process.The AmStriking interindividual differences exist between d- and
l-MPH metabolism and disposition and have consistently
been demonstrated in enantiospeciﬁc investigations. The
major pathway mediating the metabolism of MPH is rapid
deesteriﬁcation. The most common formulation of MPH
is the racemicmixture of d-threo-(R,R)- and l-threo-(S,S)-MPH
with the d-isomer regarded as the active isomer.7,8 The pri-
mary metabolic pathway governing the metabolism of
both d- and l-MPH is deesteriﬁcation to the inactive metab-
olite, ritalinic acid (RA) (Figure S1 available online).9 This
process, mediated by CES1, is stereoselective and heavily
favors thehydrolysis of the l-isomer.10 Indeed, pharmacoki-
netic racemic-MPH studies, which have employed enantio-
selective analytical methods, have consistently demon-
strated that the l-isomer accounts for only a small fraction
of the total circulating blood concentrations of MPH with
the predominant circulating species being the d-MPH iso-
mer.7,11 Furthermore, the plasma half-life (t1/2) of d-MPH
ismarkedly longer than that of l-MPH. The presystemicme-
tabolism and clearance of dl-MPH is an enantioselective
process resulting in markedly higher plasma concentra-
tions of d-MPH relative to l-MPH. In an enantiospeciﬁc
study of MPH administered intravenously, both isomers
exhibited similar distribution characteristics, although the
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In a number of other studies utilizing various oral formula-
tions, the area under the plasma concentration versus time
curve (AUCinf) value for the l-isomer has been reported to
only reach ~1%–5% of that of d-MPH.12
Recently, in the course of conducting a randomized
three-way crossover study of racemic MPH at a single
dose of 0.3 mg/kg aimed at investigating the interaction
of MPH and ethanol in normal volunteers (n ¼ 20), we
identiﬁed a male white subject who displayed a highly
unusual concentration-versus-time proﬁle suggestive of
a metabolic deﬁciency in CES1.13 That study included
serial blood sampling, enantioselective MPH and metabo-
lite determinations, and repeated hemodynamic measure-
ments in the controlled environment of a clinical research
unit. Further details of that study are described else-
where.13 The present report utilizes data from one of the
three phases studied in which research subjects received
a single weight-based dose of racemic MPH only.
A pharmacokinetic analysis of the subject’s blood con-
centrations employing enantioselective methodologies
revealed striking elevations in everymeasured pharmacoki-
netic parameter relative to the other 19 study subjects
(Figure S2). For example, the observed maximum plasma
concentration (Cmax) for total MPH (i.e., combined d- and
l-isomers) was ~7-fold higher than the mean determined
for the remaining subjects. Furthermore, an unprecedented
observation was the extraordinarily high concentrations of
the l-MPH isomeroverall and inparticular relative tod-MPH
(Cmax¼ 62 ng/ml) (Figure 1). This concentration was ~100-
fold higher than that determined in study peers and typical
literature values.10,13 Finally, the coadministration of MPH
with ethanol normally results in the formation of the trans-
esteriﬁcation metabolite ethylphenidate, also a metabolic
process known to be speciﬁcally mediated by CES1.14 It
wasnoted thatdetectable concentrationsof ethylphenidate
were present in every study subject during the twophases in
Figure 1. The Plasma Concentrations of d- and l-MPH in the
Aberrant Metabolizer versus Study Peers
The plasma concentration versus time curve presenting individual
isomer concentrations (d- versus l-MPH) in the aberrant metabo-
lizer compared to the mean values of 19 study peers following
a single 0.3 mg/kg dose of racemic MPH.1242 The American Journal of Human Genetics 82, 1241–1248, JunewhichMPH and ethanol were combined with exception of
this single individual.
We hypothesized decreased or absent activity of CES1 as
the underlying cause of the peculiar pharmacokinetics ob-
served in this individual. This report describes the discov-
ery of two variants that were present in the CES1 gene of
this individual as well as his biological parents. We also re-
port the frequency of these variants in representative racial
and ethnic populations. Furthermore, we describe a mark-
edly different hemodynamic response in this subject after
MPH administration, suggesting that these mutations may
well contribute to clinically signiﬁcant alterations in drug
response and tolerability to MPH. Finally, we conducted
in vitro functional studies, which demonstrate that cata-
lytic activity (i.e., ester hydrolysis) toward MPH as well as
a model substrate p-nitrophenyl acetate (PNPA) are signiﬁ-
cantly decreased in these two CES1 mutants.
Material and Methods
Identiﬁcation of CES1 Genetic Variants
Total genomic DNAwas extracted fromwhole blood forCES1DNA
sequence analysis. DNA sequencing, initial SNP identiﬁcation, and
mutant-sequence veriﬁcation was performed by SeqWright, Labo-
ratories (Houston, TX, USA). Fifty-two custom primers were used
in the bidirectional sequencing of all 14 CES1 exons, including
50–200bpofﬂanking intronic regionat eachexon (GenBankacces-
sion numbers: genomic reference, AB119997; cDNA, AB119995).
Introns were not investigated further. Sequence at the 50 end
extended~12bpupstreamof exon1andat the 30 end~13bpdown-
stream of exon 14. Additional primer sets used for verifying the
two described mutations are listed in Table 1.
Sequence delineation and base calling was performed with auto-
mated ﬂuorescent DNA sequencers (ABI model 3730xl; Applied
Biosystems, Foster City, CA, USA). Cycling conditions were as fol-
lows: 30 cycles of 95C for 30 s, 50C–60C (depending on Tm) for
30 s, and 70C for 1 min.
All procedures were approved by the Medical University of
South Carolina Institutional Review Board and were performed
only after obtaining written informed consent. In the case of addi-
tional DNA samples obtained from additional subjects for pur-
poses of determining SNP frequency in the general population,
all procedures were approved by the University of Florida Institu-
tional Review Board, and written informed consent was obtained.
Genotyping for CES1 Variants and Determination
of SNP Frequency
Genotyping assays were performed in duplicate and analyzed
on a Bio-Rad iCycler iQ Multicolor real-time detection system.
Table 1. Primers for Mutants Verification Used by SeqWright
Laboratories
Names Sequences
Exon 4 forward 50-TGATGGGAGTGTCCTCCCGAAG-30
Exon 4 reverse 50-GGGTAGGTAGTGTGTCCAATTAC-30
Exon 6 forward 50-AGGAAGACTTCCACCTCCTTG-30
Exon 6 reverse 50-AGGAGTGTGGTCACACAGATAG-302008
Real-time polymerase chain reaction (PCR) allelic discrimination
assays were designed with Assay by Design service and the speciﬁc
variants in the CES1 gene, p.Gly143Glu (genomic: nt 9486; cDNA:
nt 428, dbSNP ss number: 99307125) and p.Asp260fs (genomic: nt
12754; cDNA: nt 780, dbSNP ss number: 99307126), were identi-
ﬁed with ﬂuorogenic TaqMan Probes. The sequences of primers
and probes are shown in Table 2.
Real-time PCR ampliﬁcations were carried out in a 10 ml reaction
mix containing 5 ng genomic DNA, 900 nM of each primer,
200 nM of each probe and 5 ml of 23 TaqMan Universal PCR Mas-
ter Mix (contains PCR buffer, passive reference dye ROX, deoxynu-
cleotides, uridine, uracil-N-glycosylase, and AmpliTaq Gold DNA
polymerase; Perkin-Elmer, Applied Biosystems, Foster City, CA,
USA). Cycle parameters were as follows: 95C for 10 min and
then 50 cycles of 92C for 15 s and 60C for 1 min. Real-time ﬂuo-
rescence detection was performed during the 60C annealing and
extension step of each cycle. We used the IQ software to plot and
automatically call genotypes on the basis of a two-parameter plot
with ﬂuorescence intensities of FAM and VIC at 49 cycles.
Genomic DNA from 13 additional participants (ten male and
three female individuals of European descent) from the same phar-
macokinetic study as the aberrant metabolizer was also screened
for CES1 variants. These participants exhibited ‘‘normal’’ MPH
concentrations consistent with those typically observed in re-
search subjects and available patient studies. The aberrant metab-
olizer’s biological parents were also screened for the CES1 variants.
In order to estimate the allelic frequency of these CES1 variants in
the general white population, a genomic DNA panel (HD100CAU)
representing a cohort of 100 self-declared individuals of European
descent (51 males, 49 females) obtained through Coriell Cell Re-
positories (Coriell Institute, Camden, NJ, USA) was screened. Addi-
tionally, genomic DNA samples collected from various self-identi-
ﬁed racial and ethnic groups during the course of participation
in a large multicenter clinical study of combination antihyperten-
sive treatment (INternational VErapamil SR/Trandolapril Study
[INVEST]) were also available for analysis.15 This group consisted
of 355 additional white subjects, 117 black subjects, 299 subjects
of Hispanic ethnicity, and 54 Asian individuals. The aberrant me-
tabolizer, his parents, and study peers were not included in the cal-
culation of allelic frequency because a priori information regard-
ing their CES1 activity was known to investigators.
Analysis of Pharmacokinetic, Hemodynamic,
and Statistical Data
Standard pharmacokinetic analyses were applied to the MPH data
with WinNonLin software (Pharsight, Mountainview, CA, USA)
and are described in a previous publication.13 We analyzed the
Table 2. Sequences of Primers and Probes Used for Real-Time
PCR Allelic Discrimination Assay
Names Sequences
p.Gly143Glu forward 50-CCCAGGTGATGGTGTGGAT-30
p.Gly143Glu reverse 50-GCCAGCCCATCATAGGTTGA-30
p.Gly143Glu Probe, Vic labeled 50-CCATCAGCCCCCCTC-30
p.Gly143Glu Probe, Fam labeled 50-CCATCAGCTCCCCTC-30
p.Asp260fs forward 50-TGGCCCTCACTTCTGTTCTG-30
p.Asp260fs reverse 50-CCAGCCGGAGACCTACCT-30
p.Asp260fs probe, Vic labeled 50-AAAGGTGATGTCAAGCC-30
p.Asp260fs probe, Fam labeled 50-AAAGGTGAGTCAAGCC-30The AmAUC, Cmax, and t1/2 with the extreme studentized deviate (ESD)
single-outlier procedure16 to determine whether the parameter
measurements for the slow metabolizer constituted true statistical
outliers. For each parameter, the ESD procedure conﬁrmed the
measurement as an outlier at the p < 0.01 level. Because this pro-
cedure is known to be conservative, the data from the aberrant
metabolizer were reassessed with a similar procedure with respect
to the normal participants only.
To determinewhether the slowmetabolizer ofMPH experienced
signiﬁcantly different pharmacodynamic effects as a result of ele-
vated MPH blood concentrations, we examined hemodynamic
data that had been collected at eight time points afterMPH admin-
istration during the study.13 Beyond each subject’s measurements
of systolic blood pressure (SBP), diastolic blood pressure (DBP),
and heart rate (HR), the mean arterial pressure (MAP) was also cal-
culated according to the following formula: MAP ¼ DBP þ 1/3
(SBP – DBP).
We considered the set ofmeasures for each endpoint to be amul-
tivariate vector and assessed theMahalanobis distance for subject’s
measurements. The Mahalanobis distance, a measure of distance
from a central multivariate mean relative to the variance of the
endpoints, is useful for identifying outliers via referral to the F dis-
tribution. This analysis assumes no explicit model of time effects
on the vital signs but recognizes the potential correlation between
the repeated measures over time on each participant and tests for
simultaneous differences from the mean over the set of time
points while controlling the type I error rate. For each of the
four endpoint vectors, we tested the a priori hypothesis that the
slow metabolizer’s measurements were outliers by comparison to
Wilk’s critical values (a ¼ 0.0125, critical value: 13.8).17 Because
we were only testing outlier status for this single participant, no
Bonferroni corrections were made within participants; however,
we performed each test at the Bonferroni-corrected a ¼ 0.0125
level to adjust for the four endpoints being tested. There were little
differences in plasma MPH concentrations between the slow me-
tabolizer and his study peers during the initial 0–1.5 hr time frame
(Figure S2), and such a result is probably because of a delay in tab-
let disintegration, dissolution, and absorption. After this initial pe-
riod, MPH is subject to ﬁrst-pass metabolism and CES1-mediated
stereoselective hydrolysis, and the two concentration-versus-
time curves rapidly diverge from one another (Figure 1 and
Figure S2). Therefore, on the basis of this ﬁnding and a visual ex-
amination of the data, it was decided that a second analysis that
excluded measurements taken during the 0–1.5 hr time points
would be more appropriate.
The allele frequency was determined by gene counting. Addi-
tionally, we tested genotype frequencies within individual sexes
and ethnicity groups for any signiﬁcant departure from the
Hardy-Weinberg Equilibrium, using the Chi square test with one
degree of freedom.
In Vitro Functional Studies
Establish Cell Lines Stably Expressing Wild-Type and Mutant CES1
Human CES1A1 cDNA cloned into a pCMV-SPORT6 vector was
purchased from ATCC. A construct capable of expressing human
CES1 in Flp-In-293 cells (Invitrogen, Carlsbad, CA, USA) was
generated with a TA cloning strategy. In brief, the human
CES1A1 gene was ampliﬁed via PCR, inserted into pcDNA5/FRT/
V5-His-TOPO vector, and transformed into One Shot TOP10
Chemically Competent E. coli cells (Invitrogen). The desired plas-
mid was designed such that the recombinant CES1 would beerican Journal of Human Genetics 82, 1241–1248, June 2008 1243
expressed in mammalian cells with a V5-His tag to facilitate detec-
tion and puriﬁcation. Additionally, we generated another plasmid
by inserting a stop codon afterCES1A1 gene to yield the constructs
expressing CES1 without V5-His tag. Western blotting revealed
that the detectable expression levels of V5-His-tagged CES1 were
signiﬁcantly lower than that of untagged CES1; such a result
may be caused by incorrect protein folding of tagged CES1.
Thus, only untagged CES1 and its associated mutants were used
in the enzymatic hydrolysis study. Two constructs of CES1 muta-
tions, p.Gly143Glu and p.Asp260fs, were generated with a site-
directed mutagenesis assay. All constructs were subjected to DNA
sequencing analysis for conﬁrmation that the desired plasmids
were obtained. The identiﬁed CES1A1 plasmids (WT, p.Gly143-
Glu, and p.Asp260fs) were cotransfected with a pOG44 plasmid
at a ratio of 1:10 into Flp-In-293 cells with Lipofectamine 2000
(Invitrogen). Additionally, the self-ligated pcDNA5/FRT/V5-His-
TOPO vector was included as a vector control. Twenty-four hours
after transfection, cells were washed with PBS and fresh complete
medium (Dulbecco’s modiﬁed Eagle’s medium containing 10%
fetal-bovine serum) was added. Forty-eight hours after transfec-
tion, cells were split at a 1:10 ratio and cultured at 37C until
cell attachment was observed. Culture mediumwas then removed
and replenished with complete medium supplemented with the
selecting antibiotic hygromycin B (100 mg/mL). The cell lines
stably expressingWT, p.Gly143Glu, and p.Asp260fs CES1were ob-
tained only after a minimum 3 week selection process employing
hygromycin B. Each generated cell line was identiﬁed by both
expression detection and enzymatic-function assays.
Enzymatic-Function Study
After attaining ~95% conﬂuence, cells were rinsed and harvested
in PBS containing 10 mM HEPES (pH 7.4). The cell suspension
was then sonicated, and the supernatant 9000 (S9) fraction was
collected by centrifugation at 9000 g for 30 min at 4C. The pro-
tein concentration was determined using a Pierce BCA assay kit
(Rockford, IL, USA).
The hydrolysis of PNPA was carried out in 96-well culture plates
at 37C in a ﬁnal volume of 200 ml. The S9 of cells expressing WT
and mutant CES1 were diluted in reaction buffer (PBS containing
10 mMHEPES [pH 7.4]) with a ﬁnal S9 concentration of 20 mg/mL
and preincubated at 37C for 10 min. We initiated the reaction by
adding a range of concentrations of PNPA (20–1000 mM). The for-
mation of p-nitrophenol (PNP) from PNPA was determined by the
absorbance at 405 nm after incubation at 37C for 10 min.
For the study of MPH hydrolysis, the reaction was conducted in
1.5ml Eppendorf tubes with a ﬁnal S9 concentration of 0.5mg/mL
at a total volume of 100 mL. Prior to incubations, d- and l- MPH so-
lutions were prepared freshly in 50 ml reaction buffer and then
mixed with 50 ml of S9 with ﬁnal substrate concentrations ranging
from 20 mM to 1000 mM. After incubation at 37C for 2 hr, the
reaction was terminated by addition of 500 ml of methanol. The
Table 3. Hemodynamic Parameters in the Slow Metabolizer
versus the 19 Study Peers Prior to Dosing with
Methylphenidate and the Maximum Values Obtained
Predose Maximum Value
Hemodynamic parameter Mean (SD) Outlier Mean (SD) Outlier
Systolic blood pressure 114 (12) 100 120 (10) 138
Diastolic blood pressure 65 (9) 60 68 (8) 78
Mean arterial pressure 82 (9) 73 85 (8) 97
Pulse 62 (10) 70 74 (11) 931244 The American Journal of Human Genetics 82, 1241–1248, Juneprecipitated protein was then removed by centrifugation
(20,000 g for 5 min at 4C). Concentrations of the primary phase
I MPH metabolite produced via hydrolysis, RA, was determined
with an established HPLC method described below.
Both PNPA and MPH were spontaneously hydrolyzed in the
reaction buffer. Thus, after the enzymatic assay, the values deter-
mined for spontaneous PNP and RA hydrolysis were subtracted
from the total PNP and RA production. Notably, the empty-vec-
tor-transfected cells did not display anymeasurable catalytic activ-
ity or expression of CES1. All collected data were ﬁt to the Michae-
lis-Menten equation, and kinetic parameters were calculated with
nonlinear regression analysis with Graphpad Prism software
(Graphpad Software, San Diego, CA, USA).
HPLC Analysis
A high-performance liquid chromatography (HPLC) method was
employed to determine RA concentrations on the basis of the
method described by Soldin and associates.18 The HPLC system
consisted of an Agilent 1100 module, a C18 reversed-phase
column (250 3 4.6 mm, 5 mm) preceded by a 4 mm 3 3 mm
C18 guard column (Phenomenex, Torrance, CA, USA), and a di-
ode-array detector. The separation was performed with acetoni-
trile/20 mM KH2PO4, pH 3.8 (16/84, v/v) with a ﬂow rate of
1.0 mL/min and column temperature set at 40C. The detection
wavelength was set at 192 nm. RAwas eluted at 7.6min. The lower
limit of quantiﬁcation of RA was 0.2 mM.
Results
Pharmacokinetic Statistical Analysis
On the basis of the ESD analyses applied to the data, we
estimated the subject’s AUC, Cmax, and t1/2 values of
d-MPH were 7.3, 4.9, and 5.2 standard deviations from
the mean of the other 19 normal volunteers, respectively
(Table S1). These results demonstrate that this aberrant
metabolizer’s individual key pharmacokinetic parameters
(i.e., AUCinf, Cmax, and t1/2) were statistical outliers sugges-
tive of a metabolic abnormality.
Pharmacodynamic Statistical Analysis
and Consequences of a CES1 Deﬁciency
When all data including that from the time points 0–1.5 hr
were included in the data set, the slow metabolizer was an
outlier for the endpoint of MAP (distance: 18.0), whereas
SBP approached statistical signiﬁcance (distance: 13.3
compared to the critical value 13.8). However, the subject
was not an outlier for the measures of DBP and HR.
When the time frame during which MPH absorption
generally occurs after oral administration was excluded
(i.e., 0–1.5 hr) statistical outlier status was achieved for
all hemodynamic measures (i.e., SBP, DBP, HR, and MAP).
Values prior to dosing as well as maximum values for the
slow metabolizer versus the other 19 subjects are shown
in Table 3.
Identiﬁcation of CES1 Polymorphisms
All 14 exons of the CES1 gene were sequenced. Two nonsy-
nonymous, coding region variants of CES1 were identiﬁed
(Figure S3). The ﬁrst was a substitution (p.Gly143Glu) in2008
exon 4 at the second nucleotide (nt) of codon 143 (geno-
mic: nt 9486; cDNA: nt 428), changing G to A (GGG/
GAG). This results in the nonconservative amino acid
substitution of glycine 143 to glutamic acid (Gly143Glu).
The second variant identiﬁed (p.Asp260fs) was a deletion
(T/) occurring in exon 6 at the last nucleotide (genomic:
nt 12754; cDNA: nt 780) of codon 260 (GAT/GA-G).
This results in a frameshift (p.Asp260fs) mutation that
changes aspartic acid 260 to glutamic acid and alters the
next 39 residues from the wild-type (WT) sequence, before
truncating early at a premature stop codon (Figure S3).
Thus, wild-type CES1 and the substitution (p.Gly143Glu)
variant are each 567 amino acids long, but the frameshift
(p.Asp260fs) variant is limited to 298 amino acids (the ﬁrst
259 wild-type followed by 39 missense residues and early
truncation).
Allelic Frequency of Mutations in Speciﬁc Racial
and Ethnic Groups
The allelic frequency of these CES1 variants was deter-
mined utilizing the described genomic DNA data set. Of
those, 455 white subjects, 117 black subjects, and 299 His-
panic individuals were studied, and a total of 34, 10, and
12 were identiﬁed as heterozygous for p.Gly143Glu, re-
spectively. Thus, the minor allele frequency (MAF) of
p.Gly143Glu is estimated to be 3.7%, 4.3%, and 2.0% in
white, black, and Hispanic populations, respectively. There
was no deviation fromHardy-Weinberg Equilibrium in any
of the populations in which the variant was detected.
Additionally, p.Gly143Glu was not identiﬁed in 54 Asian
subjects studied, indicating the variant should be consid-
ered as rare in Asian population (Table S2). The p.Asp260fs
appears to be a rare mutation being found in none of the
925 subjects genotyped with a frequency substantially
lower than 1%. There were no statistically signiﬁcant dif-
ferences between sexes in the MAF of p.Gly143Glu in
any racial or ethnic group. Lastly, genotyping of each of
Figure 2. Hydrolysis of PNPA by CES1 and Its Mutants
Cell S9 fractions prepared from cells transfected with cDNA con-
structs encoding WT, p.Gly143Glu, and p.Asp260fs CES1 were
assayed for their catalytic activity to PNPA hydrolysis. The hydro-
lytic product PNP was monitored by the absorbance at 405 nm after
incubating PNPA with cell S9 (20 mg/ml) at 37C for 10 min. Data
were expressed as the mean5 SD (n ¼ 3).The Amthe aberrant metabolizer’s biological parents revealed
that the father was heterozygous for p.Gly143Glu, whereas
the mother was heterozygous for p.Asp260fs. This indi-
cates that the two variants are not in linkage disequilib-
rium and are thus found on separate alleles.
Enzymatic Activity of CES1 and Its Mutants on MPH
and PNPA Hydrolysis
We determined kinetic parameters (Vmax and Km) of CES1
and its mutations for PNPA and d- and l-MPH bymeasuring
the rate of enzymatic production of PNP and RA at differ-
ent substrate concentrations and ﬁtting the data to the
Michaelis-Menten equation with nonlinear regression
analysis.
PNPA is a sensitive and established model substrate of
CES1 as well as other human esterases. The results demon-
strated that WT CES1 exhibited signiﬁcant catalytic activ-
ity on PNPA hydrolysis with Vmax and Km values of 493.9
nmole/min/mg protein and 106.6 mM, respectively. Signif-
icantly decreased enzymatic activity of p.Gly143Glu and
p.Asp260fs were observed. TheVmax values of p.Gly143Glu
and p.Asp260fs were only 18.6% and 5.7% of that of WT
CES1, respectively. The Km value for p.Gly143Glu is com-
parable to that of WT, whereas p.Asp260fs is ~9.5 times
greater than that of WT, indicating the afﬁnity of
p.Asp260fs (but not p.Gly143Glu) to its recognized sub-
strate was noted to be signiﬁcantly decreased (Figure 2
and Table 4).
The MPH hydrolysis study demonstrated that WT CES1
exhibited substantial stereoselectivity relative to catalytic
efﬁciency with l-MPH favored over the d-isomer with
a Vmax of 1701.0 and 177.2 pmole/min/mg protein,
Table 4. Kinetic Parameters of Enzymic Hydrolysis of PNPA,
l-MPH, and d-MPH
Substrates Enzymes Vmax Km Vmax/Km
PNPA
WT 493.95 14.3 106.65 10.1 4.63
p.Gly143Glu 92.05 2.9 93.2 5 9.8 0.99
p.Asp260fs 28.05 6.1 950.45 352.1 0.03
l-MPH
WT 1701.05 196.5 775.75 161.9 2.19
p.Gly143Glu N.D. N.D. N.D.
p.Asp260fs N.D. N.D. N.D.
d-MPH
WT 177.25 29.6 663.55 210.0 0.27
p.Gly143Glu N.D. N.D. N.D.
p.Asp260fs N.D. N.D. N.D.
Values represent the mean 5 SD (n ¼ 3). N.D., not detectable. Km values
are in micromolar. Vmax values for PNPA and MPH are in nmole/min/mg
protein and pmole/min/mg protein, respectively. Vmax/Km values for
PNPA and MPH are in ml/min/mg protein and ml/min/mg protein, respec-
tively.erican Journal of Human Genetics 82, 1241–1248, June 2008 1245
respectively. These stereoselective actions were entirely
consistent with our previous clinical observations and
those of other investigators.10,13,19 The catalytic activity
produced by CES1 mutants, p.Gly143Glu, and p.Asp260fs
toward MPH hydrolysis were too low to be determined
under our experimental conditions even when a very
high S9 concentration (2 mg/ml) was employed (Figure 3
and Table 4).
Discussion
This study identiﬁed two variants in the CES1 gene. One in
exon 4 is located in codon 143 (GGG/GAG) and leads to
the nonconservative glycine 143 to glutamic acid amino
acid substitution (p.Gly143Glu). A deletion in exon 6 at
codon 260 results in a frameshift mutation that alters res-
idues 260–299 before truncating early at a premature
stop codon (p.Asp260fs). These mutations led to grossly
elevated total MPH blood concentrations along with a dis-
tortion in the typical isomer disposition within an individ-
ual who was heterozygous for both mutations on separate
alleles of the CES1 gene.
In order to determine whether the variations in CES1
activity led to a quantiﬁable difference in the pharmacody-
namic effects of MPH, we compared the hemodynamic
response of this individual to his study peers. The subject
was an outlier for all endpoints (SBP, DBP, HR, and MAP)
with data points obtained 1.5 hr after MPH administration.
Importantly, therapeutic doses of MPH can occasionally
cause adverse cardiovascular effects.20–22 In rare instances,
stroke or sudden death has been reported in patients with
underlying risk factors (FDA, FDA Directs ADHD Drug
Figure 3. Catalytic Activity of WT CES1 and Its Variants on
d-MPH and l-MPH Hydrolysis
Afterd- and l-MPH (20–1000mM)were incubatedwith S9 (500mg/ml)
from cells transfected with WT, p.Gly143Glu, and p.Asp260fs CES1
at 37C for 2 hr, the produced RA was measured by HPLC assay.
Significant catalytic stereoselectivity of WT CES1 was found in cat-
alyzing d- and l-MPH hydrolysis. p.Gly143Glu and p.Asp260fs failed
to show any hydrolytic activity on both d- and l-isomer of MPH. Data
are means5 SD for three independent experiments.1246 The American Journal of Human Genetics 82, 1241–1248, JunManufacturers to Notify Patients about Cardiovascular Ad-
verse Events and Psychiatric Adverse Events). The present
results suggest a potential for an increased risk of adverse
events in individuals with either identiﬁed CES1 variants,
a risk that would be expected to increase with the thrice
daily dosing typically recommended with immediate re-
lease MPH or the use of the once daily formulations that
presently dominate the market.7,11
To reveal the molecular genetic basis of the profoundly
altered pharmacokinetics and enhanced pharmacody-
namic effects of MPH in the deﬁcient metabolizer, we in-
vestigated the catalytic function of each CES1 variant with
the cells stably expressing WT CES1, p.Gly143Glu, and
p.Asp260fs. The results demonstrated that the catalytic
efﬁciency of CES1 was dramatically decreased in p.Gly143-
Glu and p.Asp260fs. This observation is in good agreement
with the hypothesis of CES1-mediated catalysis mecha-
nism recently proposed.23 The CES1 enzyme belongs to a
larger family of serine hydrolases, which include human
acetylcholinesterase (AcChE) and butyrylcholine esterase
(BuChE). Crystal structures of CES1, AcChE, and BuChE
indicate that each has an analogous active-site groove con-
taining a catalytic triad consisting of a serine, a glutamic
acid, and a histidine residue.23 For CES1, the correspond-
ing active-site triad residues are serine 221 (S), glutamic acid
354 (E), and histidine 468 (H; shown in bold in Figure S3).
A series of three consecutive glycine residues is also located
in the active site of CES1 (Gly141–143) and create what is
now referred to as an oxyanion hole. The oxyanion hole is
thought to stabilize substrate-enzyme intermediates and,
thus, would prove fundamental to CES1 functionality.23
The catalytic triad and oxyanion hole are evolutionarily
conserved both across species and within related serine
hydrolases.23 In p.Asp260fs, the subsequent frameshift
and early truncation as a result of deletion of nucleotide
780 results in a protein missing two of the three conserved
catalytic-triad residues (Figure S3). However, the apparent
rarity of the p.Asp260fs indicates this mutation is of con-
siderably less clinical concern than p.Gly143Glu. When
the glycine in BuChE (analogous to Gly143 in CES1) was
mutated, both substrate afﬁnity and catalysis were mark-
edly reduced or abolished.24 This suggests that the muta-
tion resulting in substitution of Gly143 with glutamic
acid (i.e., p.Gly143Glu) is of critical importance and could
probably result in dysfunctional CES1. Taken together,
these ﬁndings support the hypothesis that both identiﬁed
CES1 variants are likely to result in signiﬁcant loss of CES1
activity, which has been demonstrated by our in vitro
functional studies, and either is sufﬁcient to signiﬁcantly
disrupt catalytic activity. The aberrantmetabolizer was het-
erozygous for bothmutations, and eachmutation occurred
on a different allele. Because of the estimated frequencies
of each variants, having one of these mutants on both al-
leles is expected to be an extremely rare occurrence. Never-
theless, the serendipitous identiﬁcation of the subject’s
phenotype was key to discovering and exploring the two
variants described.e 2008
The CES1 enzyme catalyzes the hydrolysis of drugs from
numerous classes. Ester cleavage generally produces inac-
tive metabolite(s) as in the case of MPH.1,11 However,
CES1 is also known to be involved in the generation of
active metabolites including the conversion of heroin to
monoacetylmorphine andmorphine.1,2 Of perhaps greater
signiﬁcance is the role of CES1 in the activation of prodrugs
including a number of ACE inhibitors (e.g., quinapril) and
the anti-inﬂuenza agent oseltamivir.25,26 There is at least
one research report in which a SNP in the promoter region
of CES1, A(816)C, favorably inﬂuenced the antihyperten-
sive response to the prodrug angiotensin-converting en-
zyme inhibitor imidapril, which highlights the importance
of adequate and functional CES1 when administering pro-
drug substrates of this enzyme.27 Additionally, functional
CES1 is required for the mediation of transesteriﬁcation
reactions.14 With regard to drugs of abuse, the existence
of an unrecognized CES1 deﬁciency could potentially lead
to toxicities and/or fatal exposures misinterpreted as inten-
tional or accidental drug overdoses if the judgment were
made on the basis of antemortem or postmortem concen-
trations. Furthermore, these hydrolytic reactions can pro-
ceed on a stereoselective basis resulting in a distortion of
the anticipated disposition of a racemic compound such
as dl-MPH (Figure 1).10 The effect of each individual variant
on the metabolism of other substrates will need to be
further investigated. Finally, the presence of dysfunctional
ornonfunctionalCES1may result in apoor response to ava-
riety of prodrugs formulated as esters for the purpose of en-
hanced bioavailability3 because of the inability of CES1 to
cleave and liberate the active therapeutic moiety.
Further studies are needed to deﬁne the clinical signiﬁ-
cance of each allele as it relates to drug response and adverse
events. Beyond MPH, these variants in the CES1 gene are
pertinent to the use of a diverse group of therapeutic agents
aswell as individuals abusing illicit substances. Genotyping
individuals participating inwell-designed clinical studies of
known CES1 substrates will be an initial step in evaluating
the true clinical signiﬁcance of these variants and their con-
tribution to individualized pharmacotherapy.
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Three ﬁgures and two tables are available at http://www.ajhg.org/.
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